Suppr超能文献

相似文献

1
Strength Testing in Motor Neuron Diseases.
Neurotherapeutics. 2017 Jan;14(1):154-160. doi: 10.1007/s13311-016-0472-0.
3
Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Neurology. 2009 Jun 2;72(22):1948-52. doi: 10.1212/WNL.0b013e3181a8269b.
7
Beta-band intermuscular coherence: a novel biomarker of upper motor neuron dysfunction in motor neuron disease.
Brain. 2012 Sep;135(Pt 9):2849-64. doi: 10.1093/brain/aws150. Epub 2012 Jun 22.
8
Hemiplegic ALS: Mills syndrome.
Neurology. 2005 Jun 14;64(11):1984-5. doi: 10.1212/01.WNL.0000163995.62871.A4.
10
Interpretation of electrodiagnostic findings in sporadic progressive muscular atrophy.
J Neurol. 2008 Jun;255(6):903-9. doi: 10.1007/s00415-008-0813-y. Epub 2008 May 19.

引用本文的文献

2
Variability between Different Hand-Held Dynamometers for Measuring Muscle Strength.
Sensors (Basel). 2024 Mar 14;24(6):1861. doi: 10.3390/s24061861.
3
α-Gal Nanoparticles in CNS Trauma: II. Immunomodulation Following Spinal Cord Injury (SCI) Improves Functional Outcomes.
Tissue Eng Regen Med. 2024 Apr;21(3):437-453. doi: 10.1007/s13770-023-00616-y. Epub 2024 Feb 3.
5
Acute Toxic Effects of Tetrodotoxin in Mice via Intramuscular Injection and Oral Gavage.
Toxins (Basel). 2023 May 13;15(5):334. doi: 10.3390/toxins15050334.
7
Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy.
Eur J Neurol. 2022 Dec;29(12):3666-3675. doi: 10.1111/ene.15542. Epub 2022 Sep 13.
9
Progressive arm muscle weakness in ALS follows the same sequence regardless of onset site: use of TOMS, a novel analytic method to track limb strength.
Amyotroph Lateral Scler Frontotemporal Degener. 2021 Aug;22(5-6):380-387. doi: 10.1080/21678421.2021.1889000. Epub 2021 Feb 23.

本文引用的文献

1
Quantitative strength testing in ALS clinical trials.
Neurology. 2016 Aug 9;87(6):617-24. doi: 10.1212/WNL.0000000000002941. Epub 2016 Jul 6.
2
Six-minute walk test is reliable and valid in spinal muscular atrophy.
Muscle Nerve. 2016 Nov;54(5):836-842. doi: 10.1002/mus.25120. Epub 2016 May 13.
3
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):426-435. doi: 10.3109/21678421.2016.1148169. Epub 2016 Mar 16.
4
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
Lancet Neurol. 2014 Nov;13(11):1083-1091. doi: 10.1016/S1474-4422(14)70222-4. Epub 2014 Oct 5.
5
Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study.
Neuromuscul Disord. 2014 Feb;24(2):134-42. doi: 10.1016/j.nmd.2013.10.011. Epub 2013 Nov 13.
6
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23.
7
A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):574-81. doi: 10.3109/21678421.2013.822517. Epub 2013 Aug 19.
8
The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS.
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):582-5. doi: 10.3109/21678421.2013.817587. Epub 2013 Aug 19.
10
Pilot trial of clenbuterol in spinal and bulbar muscular atrophy.
Neurology. 2013 Jun 4;80(23):2095-8. doi: 10.1212/WNL.0b013e318295d766. Epub 2013 May 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验